Table 1.
Treatment Sequences
| Sequence | Period 1 | Period 2 | Period 3 | Period 4 |
|---|---|---|---|---|
| ADBC (N = 8) | A | D | B | C |
| BACD (N = 8) | B | A | C | D |
| CBDA (N = 8) | C | B | D | A |
| DCAB (N = 8) | D | C | A | B |
Participants received a single oral 300‐mg dose, administered as 2 150‐mg tablets, in each of 4 treatment periods. Blood samples for PK profiles were collected over 24 hours after each dose, and treatment periods were separated by at least 5 days.
Treatment A: participants fasted overnight (no food or drink except for water for at least 6 hours before dosing); a standard high‐fat (nondairy) meal was served 3 hours after dosing.
Treatment B: a standard high‐fat (nondairy) meal was completed 4 hours before dosing.
Treatment C: a standard high‐fat (nondairy) meal was completed 2 hours before dosing.
Treatment D: a standard high‐fat meal including dairy was completed 2 hours before dosing.